Publications
Imeglimine
Mechanism of Action of Imeglimin: A Novel Therapeutic Agent for Type 2 Diabetes
Hallakou-Bozec, S., G. Vial, M. Kergoat, P. Fouqueray, S. Bolze, A.L. Borel, E. Fontaine, and D.E. Moller — 2021
Imeglimin Amplifies Glucose-stimulated Insulin Release From Diabetic Islets Via a Distinct Mechanism of Action
Hallakou-Bozec, S., M. Kergoat, P. Fouqueray, S. Bolze, and D.E. Moller — 2021
Efficacy and Safety of Imeglimin in Japanese Patients with Type 2 Diabetes: A 24-week, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2b trial
Dubourg, J., K. Ueki, J.M. Grouin, and P. Fouqueray — 2021
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial
Dubourg, J., P. Fouqueray, C. Thang, J.M. Grouin, and K. Ueki — 2021
Short-and Long-term Administration of Imeglimin Counters Cardiorenal Dysfunction in a Rat Model of Metabolic Syndrome
Lachaux, M., M. Soulie, M. Hamzaoui, A. Bailly, L. Nicol, I. Remy-Jouet, S. Renet, C. Vendeville, P. Gluais-Dagorn, S. Hallakou-Bozec, C. Monteil, V. Richard, and P. Mulder — 2020
Imeglimin Preserves Islet β-cell Mass in Type 2 Diabetic ZDF Rats
Hallakou-Bozec, S., M. Kergoat, D.E. Moller, and S. Bolze — 2020
Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects
Fouqueray, P., S. Perrimond-Dauchy, and S. Bolze. — 2020
Absence of QTc Prolongation in a Thorough QT Study with Imeglimin, a First in Class Oral Agent for Type 2 Diabetes Mellitus
Dubourg, J., S. Perrimond-Dauchy, M. Felices, S. Bolze, P. Voiriot, and P. Fouqueray — 2020
In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans
Clemence, C., P. Fouqueray, and B. Sebastien — 2020
Lack of Drug-Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers
Chevalier, C., S. Perrimond-Dauchy, J. Dubourg, P. Fouqueray, and S. Bolze — 2020
Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment
Chevalier, C., J. Dubourg, S. Bolze, and P. Fouqueray — 2020
Imeglimin Lowers Glucose Primarily by Amplifying Glucose-stimulated Insulin Secretion in High-fat-fed Rodents
Perry, R.J., R.L. Cardone, M.C. Petersen, D. Zhang, P. Fouqueray, S. Hallakou-Bozec, S. Bolze, G.I. Shulman, K.F. Petersen, and R.G. Kibbey — 2016
Imeglimin Prevents Human Endothelial Cell Death by Inhibiting Mitochondrial Permeability Transition Without Inhibiting Mitochondrial Respiration
Detaille, D., G. Vial, A.L. Borel, C. Cottet-Rouselle, S. Hallakou-Bozec, S. Bolze, P. Fouqueray, and E. Fontaine — 2016
Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-fat, High-sucrose Diet Mice Model
Vial, G., M.A. Chauvin, N. Bendridi, A. Durand, E. Meugnier, A.M. Madec, N. Bernoud-Hubac, J.P. Pais de Barros, E. Fontaine, C. Acquaviva, S. Hallakou-Bozec, S. Bolze, H. Vidal, and J. Rieusset — 2015
Imeglimin Increases Glucose-dependent Insulin Secretion and Improves Beta-cell Function in Patients with Type 2 Diabetes
Pacini, G., A. Mari, P. Fouqueray, S. Bolze, and M. Roden — 2015
The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Sitagliptin Monotherapy
Fouqueray, P., V. Pirags, M. Diamant, G. Schernthaner, H.E. Lebovitz, S.E. Inzucchi, and C.J. Bailey — 2014
The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy
Fouqueray, P., V. Pirags, S.E. Inzucchi, C.J. Bailey, G. Schernthaner, M. Diamant, and H.E. Lebovitz — 2013
Imeglimin, A Novel Glimin Oral Antidiabetic, Exhibits a Good Efficacy and Safety Profile in Type 2 Diabetic Patients
Pirags, V., H. Lebovitz, and P. Fouqueray — 2012
Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of Type 2 Diabetes
Fouqueray, P., X. Leverve, E. Fontaine, M. Baquié, C. Wollheim, H. Lebovitz, and S. Bozec — 2011
PXL065
Deuterium-Enabled Chiral Switching (DECS) Yields Chirally Pure Drugs from Chemically Interconverting Racemates
DeWitt, S., A.W. Czarnik, and V. Jacques — 2020
Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine
DeWitt, S.H. and B.E. Maryanoff — 2018